These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7200396)

  • 41. Renal excretion of magnesium and calcium in diabetes mellitus.
    Olukoga AO; Adewoye HO; Erasumus RT
    Cent Afr J Med; 1989 Apr; 35(4):378-83. PubMed ID: 2790943
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The pathological role of Bax in cisplatin nephrotoxicity.
    Wei Q; Dong G; Franklin J; Dong Z
    Kidney Int; 2007 Jul; 72(1):53-62. PubMed ID: 17410096
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of methods of evaluating nephrotoxicity of cis-platinum.
    Jones BR; Bhalla RB; Mladek J; Kaleya RN; Gralla RJ; Alcock NW; Schwartz MK; Young CW; Reidenberg MM
    Clin Pharmacol Ther; 1980 Apr; 27(4):557-62. PubMed ID: 6987030
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Fundamental studies on intravesical instillation of cis-diamminedichloroplatinum for treatment of urinary bladder tumors. II. On the effects of intravesical instillation of cis-diamminedichloroplatinum in bladder cancer patients].
    Hirao Y; Iwai A; Moriya A; Matsuki H; Yoshida Y; Komada S; Sasaki K; Kubota K; Sanma S; Babaya K
    Hinyokika Kiyo; 1985 Sep; 31(9):1565-73. PubMed ID: 4083214
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The protective effects of Ribes diacanthum Pall on cisplatin-induced nephrotoxicity in mice.
    Tilyek A; Chai C; Hou X; Zhou B; Zhang C; Cao Z; Yu B
    J Ethnopharmacol; 2016 Feb; 178():297-306. PubMed ID: 26481606
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Selective ET(A) receptor blockade protects against cisplatin-induced acute renal failure in male rats.
    Helmy MM; Helmy MW; Abd Allah DM; Abo Zaid AM; Mohy El-Din MM
    Eur J Pharmacol; 2014 May; 730():133-9. PubMed ID: 24632086
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Para-aminobenzoic acid suppression of cis-diamminedichloroplatinum(II) nephrotoxicity.
    Esposito M; Vannozzi MO; Viale M; Fulco RA; Collecchi P; Merlo F; De Cian F; Zicca A; Cadoni A; Poirier MC
    Carcinogenesis; 1993 Dec; 14(12):2595-9. PubMed ID: 8269632
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cis-platinum-induced renal sodium wasting.
    Lammers PJ; White L; Ettinger LJ
    Med Pediatr Oncol; 1984; 12(5):343-6. PubMed ID: 6541750
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Acute gentamicin-induced hypercalciuria and hypermagnesiuria in the rat: dose-response relationship and role of renal tubular injury.
    Parsons PP; Garland HO; Harpur ES; Old S
    Br J Pharmacol; 1997 Oct; 122(3):570-6. PubMed ID: 9351517
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The gingival platinum line: a new finding following cis-dichlorodiammine platinum (II) treatment.
    Ettinger LJ; Freeman AI
    Cancer; 1979 Nov; 44(5):1882-4. PubMed ID: 291474
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors.
    Sato K; Watanabe S; Ohtsubo A; Shoji S; Ishikawa D; Tanaka T; Nozaki K; Kondo R; Okajima M; Miura S; Tanaka J; Sakagami T; Koya T; Kagamu H; Yoshizawa H; Narita I
    BMC Cancer; 2016 Mar; 16():222. PubMed ID: 26979596
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cisplatin nephrotoxicity: experimental and clinical studies.
    Daugaard G
    Dan Med Bull; 1990 Feb; 37(1):1-12. PubMed ID: 2178884
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative activity and toxicity of cis-diamminedichloroplatinum (DDP) and a combination of doxorubicin, cyclophosphamide, and DDP in disseminated transitional cell carcinomas of the urinary tract.
    Khandekar JD; Elson PJ; DeWys WD; Slayton RE; Harris DT
    J Clin Oncol; 1985 Apr; 3(4):539-45. PubMed ID: 3884746
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors.
    Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
    Eur J Cancer; 2009 Dec; 45(18):3213-9. PubMed ID: 19850470
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A nephron model for study of drug-induced acute kidney injury and assessment of drug-induced nephrotoxicity.
    Qu Y; An F; Luo Y; Lu Y; Liu T; Zhao W; Lin B
    Biomaterials; 2018 Feb; 155():41-53. PubMed ID: 29169037
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Protection against cis-diamminedichloroplatinum-induced nephrotoxicity by 2,3-dimercaptosuccinic acid in rats.
    Mishima K; Hidaka S; Takamura N; Shinozawa S
    Ren Fail; 1999 Nov; 21(6):593-602. PubMed ID: 10586422
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Renal function, serum calcium and magnesium during treatment of advanced bladder carcinoma with cis-dichlorodiamineplatinum: impact of tumour site, patient age and magnesium suppletion.
    Blom JH; Kurth KH; Splinter TA
    Int Urol Nephrol; 1985; 17(4):331-9. PubMed ID: 3835175
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical trials of cis-diamminedichloroplatinum (NSC-119875).
    Lippman AJ; Helson C; Helson L; Krakoff IH
    Cancer Chemother Rep; 1973 Apr; 57(2):191-200. PubMed ID: 4126381
    [No Abstract]   [Full Text] [Related]  

  • 59. DNA damage response in cisplatin-induced nephrotoxicity.
    Zhu S; Pabla N; Tang C; He L; Dong Z
    Arch Toxicol; 2015 Dec; 89(12):2197-205. PubMed ID: 26564230
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Cisplatin and ovarian carcinoma--early detection of cisplatin-induced nephrotoxicity].
    Kobayashi H
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 Jun; 37(6):888-96. PubMed ID: 4040542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.